Beck Bode LLC increased its stake in shares of Aflac Incorporated (NYSE:AFL – Free Report) by 4.1% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 128,562 shares of the financial services provider’s stock after purchasing an additional 5,063 shares during the period. Aflac accounts for about 2.4% of Beck Bode LLC’s holdings, making the stock its 9th biggest position. Beck Bode LLC’s holdings in Aflac were worth $10,606,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors have also recently modified their holdings of AFL. Fortitude Family Office LLC purchased a new stake in Aflac in the 4th quarter worth approximately $25,000. Bruce G. Allen Investments LLC purchased a new stake in Aflac in the 4th quarter worth approximately $32,000. Harvest Fund Management Co. Ltd purchased a new stake in Aflac in the 3rd quarter worth approximately $33,000. Criterion Capital Advisors LLC purchased a new stake in Aflac in the 4th quarter worth approximately $33,000. Finally, Arlington Trust Co LLC purchased a new stake in Aflac in the 4th quarter worth approximately $35,000. 67.44% of the stock is currently owned by institutional investors and hedge funds.
Insider Activity
In related news, Director Masatoshi Koide sold 30,493 shares of the business’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $79.91, for a total transaction of $2,436,695.63. Following the completion of the sale, the director now owns 86,090 shares of the company’s stock, valued at approximately $6,879,451.90. The sale was disclosed in a legal filing with the SEC, which is available through this link. In related news, Director Thomas J. Kenny sold 5,000 shares of the business’s stock in a transaction dated Wednesday, March 20th. The shares were sold at an average price of $84.62, for a total transaction of $423,100.00. Following the completion of the sale, the director now owns 17,920 shares of the company’s stock, valued at approximately $1,516,390.40. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Masatoshi Koide sold 30,493 shares of the business’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $79.91, for a total transaction of $2,436,695.63. Following the sale, the director now directly owns 86,090 shares of the company’s stock, valued at approximately $6,879,451.90. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 46,493 shares of company stock worth $3,765,706. 0.80% of the stock is currently owned by corporate insiders.
Aflac Stock Down 1.1 %
Aflac (NYSE:AFL – Get Free Report) last issued its earnings results on Thursday, February 1st. The financial services provider reported $1.25 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.47 by ($0.22). The company had revenue of $3.78 billion during the quarter, compared to analyst estimates of $4.44 billion. Aflac had a net margin of 24.92% and a return on equity of 17.59%. During the same quarter last year, the company posted $1.29 EPS. On average, analysts anticipate that Aflac Incorporated will post 6.41 EPS for the current year.
Wall Street Analysts Forecast Growth
Several brokerages have recently issued reports on AFL. Morgan Stanley boosted their price objective on shares of Aflac from $80.00 to $84.00 and gave the company an “equal weight” rating in a research note on Monday, April 15th. The Goldman Sachs Group boosted their price objective on shares of Aflac from $61.00 to $75.00 and gave the company a “sell” rating in a research note on Tuesday, January 9th. Raymond James upped their price target on shares of Aflac from $83.00 to $88.00 and gave the stock an “outperform” rating in a research report on Friday, February 2nd. Evercore ISI cut shares of Aflac from an “in-line” rating to an “underperform” rating and upped their price target for the stock from $76.00 to $78.00 in a research report on Thursday, January 4th. Finally, Keefe, Bruyette & Woods upped their price target on shares of Aflac from $83.00 to $87.00 and gave the stock a “market perform” rating in a research report on Wednesday, April 10th. Three equities research analysts have rated the stock with a sell rating, eight have given a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $82.15.
View Our Latest Stock Report on AFL
Aflac Profile
Aflac Incorporated, through its subsidiaries, provides supplemental health and life insurance products. The company operates through Aflac Japan and Aflac U.S. segments. The Aflac Japan segment offers cancer, medical, nursing care, work leave, GIFT, and whole and term life insurance products, as well as WAYS and child endowment plans under saving type insurance products in Japan.
Recommended Stories
- Five stocks we like better than Aflac
- What to Know About Investing in Penny Stocks
- NXP Semiconductors Will Set a New High Soon: $300 in Sight
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- Hilton Demonstrates Asset Light is Right for Investors
- Investing in Commodities: What Are They? How to Invest in Them
- Boston Scientific Bucks the Medtech Slow Down and Raises Outlook
Want to see what other hedge funds are holding AFL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aflac Incorporated (NYSE:AFL – Free Report).
Receive News & Ratings for Aflac Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aflac and related companies with MarketBeat.com's FREE daily email newsletter.